Once administered (at the tumor site) and having penetrated into the skin/tumor, RSQ can bind to TLR-7 and TLR-8 on innate immune cells such as pDC and mDC, respectively, causing these cells to release a suite of cytokines [24], as well as to upregulate the expression of cell surface costimulatory molecules [24,58], thus enhancing immune stimulatory potency. The gene discussed is TLR7; the disease is neoplasm.